Form 4 Core Laboratories NV For: 5 October By Investing.com
This article reports on a Form 4 filing for Core Laboratories NV (CLB) on October 5, 2026. The brief notice confirms the filing, with Core Laboratories NV's stock symbol and a slight positive performance indicated. The rest of the content includes market data, news headlines, and navigational elements from Investing.com.
CORE LABORATORIES ANNOUNCES TIMING OF THIRD QUARTER 2026 EARNINGS RELEASE AND CONFERENCE CALL
Core Laboratories (NYSE: "CLB") will host its third quarter 2026 earnings conference call on October 29, 2026, at 7:30 a.m. CDT / 8:30 a.m. EDT. An earnings press release will precede the call on October 28, 2026, accessible via the company's website. The call will feature Larry Bruno (Chairman and CEO), Chris Hill (CFO), and Gwen Gresham (SVP Corporate Development and Investor Relations) to discuss financial and operational results.
Core Laboratories sets Oct 29 call for Q3FY26 results
Core Laboratories (NYSE: CLB) has scheduled its Q3 FY2026 earnings conference call for October 29, 2026, with the press release expected after market close on October 28, 2026. Chairman and CEO Larry Bruno, CFO Chris Hill, and SVP Gwen Gresham will lead the discussion at 7:30 am CDT / 8:30 am EDT. Stakeholders can access materials and the live webcast via the company's investor relations website.
CORE LABORATORIES ANNOUNCES TIMING OF THIRD QUARTER 2026 EARNINGS RELEASE AND CONFERENCE CALL
Core Laboratories (NYSE: "CLB") announced it will release its third-quarter 2026 financial results on October 25, 2026, after the market closes. The company will then host a conference call on October 26, 2026, at 8:30 a.m. CT to discuss these results. Interested parties can access the call via webcast or dial-in.
After the Oct. 28 close, Core Laboratories will release its results; a webcast follows next morning.
Core Laboratories (NYSE: CLB) announced that it will release its third-quarter 2026 earnings after market close on October 28, 2026. A conference call for investors and analysts will follow on October 29, 2026, at 7:30 a.m. CDT / 8:30 a.m. EDT, featuring CEO Larry Bruno, CFO Chris Hill, and SVP Gwen Gresham. The earnings press release and a replay/transcript of the call will be available on the company's website.
CORE LABORATORIES ANNOUNCES TIMING OF THIRD QUARTER 2026 EARNINGS RELEASE AND CONFERENCE CALL
Core Laboratories (NYSE: "CLB") will host its third quarter 2026 earnings conference call for investors and analysts on October 29, 2026, at 7:30 a.m. CDT / 8:30 a.m. EDT. An earnings press release will precede the call on October 28, 2026, accessible via the Company's website. The call will feature discussions on financial and operational results by Chairman and CEO Larry Bruno, CFO Chris Hill, and SVP Corporate Development and Investor Relations Gwen Gresham.
CLB Declines 35% in the Past Six Months: How to Play the Stock?
Core Laboratories (CLB) has significantly underperformed the oil and energy sector, declining 35.1% over the past six months, despite some positive developments in its Production Enhancement segment and potential for international offshore activity recovery. While proprietary technologies and an asset-light model offer long-term upside, the company faces challenges including geopolitical exposure in its Reservoir Description segment, weakened cash flow generation, and declining 2026 earnings estimates. The article concludes with a "Hold" rating, suggesting patience due to near-term pressures.
Earnings Preview: Core Laboratories (CLB) Q2 Earnings Expected to Decline
Core Laboratories (CLB) is anticipated to report a year-over-year decline in earnings and revenues for Q2 2026, with an expected EPS of $0.08 and revenues of $127.56 million. Despite a Zacks Rank of #4 (Sell), the company shows a positive Earnings ESP of +6.67%, suggesting a potential earnings beat, though this is not a strong indicator for negative-ranked stocks. Investors are advised to consider other factors beyond the earnings surprise history for this particular stock.
Zacks Research Cuts Earnings Estimates for Core Laboratories
Zacks Research has reduced its FY2026 EPS estimate for Core Laboratories (NYSE:CLB) to $0.61 from $0.62, although this is still above the $0.56 consensus. While the company beat Q2 earnings expectations with $0.11 EPS, revenue declined 4.3% year over year. Despite the lowered near-term estimates, analysts maintain a "Moderate Buy" rating with a $21 target price, and insider buying and high institutional ownership reflect continued confidence.
Zacks Research Expects Weaker Earnings for Core Laboratories
Zacks Research has lowered its Q3 2026 EPS forecast for Core Laboratories to $0.17, with full-year earnings projected at $0.56 per share. Despite beating EPS expectations in its last quarterly report, revenue decreased by 4.3% year-over-year. The stock has a "Moderate Buy" consensus rating and a $21 average price target, though it was trading down 2.3% at $12.21, significantly below its 52-week high.
Legal & General Group Plc Buys Shares of 122,575 Core Laboratories Inc. $CLB
Legal & General Group Plc recently acquired 122,575 shares of Core Laboratories Inc. (NYSE:CLB) for approximately $1.43 million, establishing a 0.27% stake in the company. Institutional ownership of Core Laboratories now stands at 97.81%. The purchase follows positive analyst sentiment, with several upgrades to "hold" or "buy" ratings and a consensus "Moderate Buy" rating with a target price of $21.00.
Core Laboratories NV (CLB) Shareholding Pattern – Promoters, FIIs & DIIs
This article details the shareholding pattern of Core Laboratories NV (CLB), an Oil & Gas Equipment company, as of September 25, 2026. It provides a comprehensive list of institutional shareholders holding more than 1% of equity, their percentage holdings, changes in shares, and filing dates dating back to December 2021. The report also includes recent insider trading activities, showing individual buy and sell transactions with dates, share numbers, prices, and values.
Bank of New York Mellon Corp Makes New Investment in Core Laboratories Inc. $CLB
Bank of New York Mellon Corp has acquired a new position in Core Laboratories Inc. (NYSE:CLB), purchasing 401,283 shares valued at approximately $4.7 million, representing about 0.87% of the company. Institutional investors now own 97.81% of CLB, and the stock received an upgrade from Johnson Rice to "buy" with a $21 price target, contributing to a "Moderate Buy" consensus rating. Despite a slight revenue decline, Core Laboratories exceeded quarterly earnings expectations, reporting $0.11 EPS against a $0.09 consensus.
Zacks Industry Outlook Highlights TechnipFMC, Oceaneering International, Inc. and Core Laboratories
The Zacks Oil and Gas-Field Services industry faces challenges such as high debt exposure and lower upstream spending, despite outperforming the S&P 500 and the broader Oil-Energy sector. Zacks highlights TechnipFMC, Oceaneering International, Inc., and Core Laboratories as companies poised to navigate these difficulties. Oceaneering International and TechnipFMC boast strong backlogs, while Core Laboratories focuses on maximizing invested capital.
BlackRock Inc. Makes New Investment in Core Laboratories Inc. $CLB
BlackRock Inc. has made a new investment in Core Laboratories Inc. (NYSE:CLB), acquiring over 7.46 million shares valued at approximately $86.9 million, giving them a 16.26% stake. Other institutional investors have also adjusted their positions, and insider activity shows CEO Lawrence Bruno increasing his ownership. The company reported beating quarterly EPS expectations but saw a 4.3% year-over-year revenue decline, with analysts maintaining a "Moderate Buy" rating and a $21 price target.
Bank of America Corp DE Has $3.77 Million Position in Core Laboratories Inc. $CLB
Bank of America Corp DE significantly increased its stake in Core Laboratories Inc. (NYSE:CLB) by 59.6% in the first quarter, now holding 224,618 shares valued at $3.77 million. This comes as Core Laboratories reported beating quarterly EPS estimates but saw a revenue decline. The company also announced a quarterly dividend and received an analyst upgrade to "buy" from Johnson Rice, contributing to a "Moderate Buy" consensus rating.
Avoiding Lag: Real-Time Signals in (CLB) Movement
This article analyzes Core Laboratories Inc. (CLB) using AI models to provide real-time trading signals and strategies. It highlights mixed sentiment, an oscillation pattern, and a significant risk-reward short setup, offering detailed entry, target, and stop-loss levels for various trading approaches. The analysis includes multi-timeframe signal assessments for near-term, mid-term, and long-term horizons, along with support and resistance levels.
Core Laboratories (CLB) Up 18.7% Since Last Earnings Report: Can It Continue?
Core Laboratories (CLB) has seen its shares jump 18.7% since its last earnings report, outperforming the S&P 500. The company reported mixed Q2 2026 results, beating earnings estimates due to its Production Enhancement segment but missing revenue expectations, primarily impacted by geopolitical conflicts. Looking ahead, CLB anticipates sequential revenue growth in Q3, driven by improving activity in South Atlantic Margin and Asia-Pacific, alongside continued technological advancements.
Core Laboratories (NYSE: CLB) director resigns over strategy dispute
Core Laboratories (NYSE: CLB) director Kwaku Temeng is resigning from the Board, effective October 1, 2026, due to disagreements over the company's strategic direction and governance practices, including succession planning and research priorities. Temeng, who chaired the Nominating Committee and served on the Compensation Committee, verbally notified the Board on August 19, 2026, and confirmed his resignation by letter on August 25, 2026. The company acknowledged his five years of service while noting the internal board differences.
Kwaku Temeng to Resign from Core Laboratories Board, Effective Oct 1, 2026
Kwaku Temeng is set to resign from the Core Laboratories (CLB) board of directors, effective October 1, 2026. His resignation stems from disagreements with the board regarding strategic direction and certain governance practices. Temeng has served on the board for over five years, holding roles as Chairman of the Nominating Committee and a member of the Compensation Committee.
Core Laboratories Inc. Announces Resignation of Kwaku Temeng as Director, Chairman of the Nominating Committee and as A Member of the Compensation Committee, Effective October 1, 2026
Core Laboratories Inc. announced the resignation of Kwaku Temeng from its Board of Directors, effective October 1, 2026. Mr. Temeng, who also chaired the Nominating Committee and served on the Compensation Committee, cited disagreements with the Board regarding the company's strategic direction and governance practices, specifically concerning succession planning and research priorities. The Board stated that his primary disagreement revolved around succession planning, a process supported by the majority of directors.
Core Laboratories Number of Employees 2026 | Employee Count & Headcount Data
Core Laboratories, Inc. (CLB) had approximately 3,318 employees worldwide as of March 2026, representing a 1.0% increase from the previous year. The company's workforce is concentrated in North America (32.8%), with an average salary of $52,895. Core Laboratories is actively hiring, with 96 active job postings in 2026, despite a negative and declining employee sentiment.
Heartland Advisors Inc. Buys Shares of 1,058,311 Core Laboratories Inc. $CLB
Heartland Advisors Inc. has acquired a significant new position in Core Laboratories Inc. (NYSE:CLB), purchasing 1,058,311 shares valued at approximately $12.3 million, representing a 2.31% stake in the company. This move comes as institutional investors now hold 97.81% of Core Laboratories' stock, and analysts have recently upgraded their ratings, setting a consensus "Moderate Buy" with a $21 target price. Despite a year-over-year revenue decline, the company surpassed quarterly EPS estimates and declared a $0.01 dividend.
Advisors Capital Management LLC Makes New $2.77 Million Investment in Core Laboratories Inc. $CLB
Advisors Capital Management LLC has made a new investment of $2.77 million in Core Laboratories Inc. (NYSE:CLB), acquiring 237,398 shares during the second quarter. This move makes Advisors Capital Management LLC a significant institutional holder, owning 0.52% of the oil and gas company. Other institutional investors also adjusted their positions in Core Laboratories, which recently reported earnings that beat analyst estimates and declared a quarterly dividend.
Q4 EPS Forecast for Core Laboratories Lifted by Analyst
Zacks Research has increased its Q4 2027 EPS forecast for Core Laboratories (NYSE:CLB) to $0.24, up from $0.23, and projected Q1 2028 EPS at $0.11. This positive revision follows Core Laboratories' recent quarterly earnings report, which saw the company beat EPS expectations ($0.11 vs. $0.09 consensus) despite a 4.3% year-over-year revenue decline. Analyst sentiment for CLB has shifted to a "Moderate Buy," with an average price target of $21.00, significantly higher than its recent opening price of $12.29, and insider buying by CEO Lawrence Bruno further underscores confidence in the stock.
101,648 Shares in Core Laboratories Inc. $CLB Purchased by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC recently purchased 101,648 shares of Core Laboratories Inc. (NYSE:CLB), valued at approximately $1.18 million, representing 0.22% of the company. Core Laboratories reported Q2 EPS of $0.11, beating estimates, but revenue missed expectations, while institutional investors now own 97.81% of the company. Analysts currently have a "Moderate Buy" rating for CLB with a $21 target price, significantly higher than its recent trading price of $12.45.
Renaissance Technologies LLC Sells 132,797 Shares of Core Laboratories Inc. $CLB
Renaissance Technologies LLC significantly reduced its stake in Core Laboratories Inc. by 72.4% in Q1 2026, selling 132,797 shares. Despite this institutional sell-off, Core Laboratories reported exceeding Q1 EPS expectations, and CEO Lawrence Bruno increased his personal holdings in the company. Analyst sentiment for Core Laboratories has also improved, with an upgrade to "buy" and a consensus target price of $21.00.
Disciplined Growth Investors (CLB) reports 6.6% Core Laboratories stake on Schedule 13G/A
Disciplined Growth Investors, Inc. has reported a 6.6% beneficial ownership stake in Core Laboratories Inc. (CLB) through a Schedule 13G/A filing. The firm beneficially owns 3,042,177 common shares, holding sole voting power over 2,961,959 shares and sole dispositive power over all 3,042,177 shares. This indicates a significant institutional investment with controlled voting and dispositive rights.
Ariel Investments (CLB) discloses 30.5% Core Laboratories stake in Schedule 13G/A
Ariel Investments, LLC has disclosed a significant stake in Core Laboratories Inc. common stock through a Schedule 13G/A filing. The investment firm beneficially owns 14,074,945 shares, which accounts for 30.5% of the outstanding common stock as of June 30, 2026. This includes sole voting power over 13,141,081 shares and sole dispositive power over all 14,074,945 shares, with Ariel Fund specifically holding 6,474,663 shares.
Core Laboratories (NYSE:CLB) Stock Rating Upgraded by Johnson Rice
Johnson Rice upgraded Core Laboratories (NYSE:CLB) from a "hold" to a "buy" rating, setting a $21.00 price target. This upgrade implies a significant upside, although the broader analyst consensus remains "Hold." The company recently reported better-than-expected EPS but missed revenue estimates, while its CEO and institutional investors have shown confidence through stock purchases and substantial ownership.
Core Laboratories' (NYSE:CLB) Weak Earnings May Only Reveal A Part Of The Whole Picture
Core Laboratories (NYSE:CLB) recently reported weak earnings, which did not significantly impact its stock price. An analysis suggests that the company's profit was boosted by US$7.1 million in unusual items in the last year, raising concerns that future profits may be weaker without these non-recurring contributions. Investors are cautioned to look beyond the statutory earnings and consider underlying weaknesses, as well as risks facing the company.
Core Laboratories (CLB) Q2 2026 Earnings Call Transcript
Core Laboratories (CLB) reported Q2 2026 earnings, showing 2% sequential revenue growth driven by increased demand for completion products, despite ongoing geopolitical conflicts in the Middle East and Russia/Ukraine impacting its Reservoir Description segment. The company highlighted improved Production Enhancement operating margins due to higher product sales and resolved tax matters, while also maintaining a commitment to shareholder returns through dividends and share repurchases. Core Labs provided Q3 2026 guidance projecting continued sequential revenue growth, primarily from international markets outside the conflict zones.
Core Laboratories N.V. (CLB) stock price, news, quote and history
This Yahoo Finance page provides comprehensive financial data for Core Laboratories N.V. (CLB), including its current stock price, dividend information, key statistics, historical data, and analyst insights. It details the company's business segments—Reservoir Description and Production Enhancement—which serve the oil and gas industry, and offers performance comparisons against the S&P 500. The page also presents earnings trends, valuation measures, and a list of comparable companies in the Oil & Gas Equipment & Services sector.
Core Laboratories' (NYSE:CLB) Weak Earnings May Only Reveal A Part Of The Whole Picture
Core Laboratories' recent earnings report, despite weak numbers, did not cause significant stock movement. The analysis suggests that the company's profit was boosted by US$7.1m in unusual items, implying that statutory profits might be better than its underlying earnings power. Investors are advised to consider these underlying weaknesses and other factors like margins, growth forecasts, and return on investment.
Core Laboratories' (NYSE:CLB) Weak Earnings May Only Reveal A Part Of The Whole Picture
Core Laboratories Inc.'s recent weak earnings report did not significantly impact its stock movement, but an analysis suggests underlying weaknesses beyond soft profit numbers. The company's profit was boosted by US$7.1 million in unusual items, which are typically not repeated, potentially leading to weaker profits next year. Investors are advised to consider these factors when evaluating the company's true earnings power.
Core Laboratories Inc (CLB) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Core Laboratories Inc (CLB), noting its current earnings forecast score of 6.00 and an average price target of $14.00 based on three analysts. It highlights an expected revenue of $131.33M for the next quarter and an anticipated EPS of $0.15. The analyst consensus is a "Hold" rating for the stock.
Dimensional Fund Advisors LP Increases Stock Position in Core Laboratories Inc. $CLB
Dimensional Fund Advisors LP has increased its stake in Core Laboratories Inc. (NYSE:CLB) by 10.0% in the first quarter, now owning 1,352,329 shares valued at $22,705,000. Other institutional investors like MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd., American Century Companies Inc., and Quantbot Technologies LP have also adjusted their positions in the oil and gas company. The article also details Core Laboratories' recent financial performance, dividend announcement, insider buying activity by CEO Lawrence Bruno, and current analyst ratings.
Core Laboratories Inc. (CLB) Stock Price, News, Quote & History
This article provides a comprehensive overview of Core Laboratories Inc. (CLB), including its current stock price, recent news like its dividend announcement, and detailed financial data. It covers company performance metrics, analyst ratings, and an in-depth profile of its operations in the oil and gas equipment and services sector. The information aims to offer potential investors a clear picture of CLB's market position and financial health.
BlackRock (CLB holder) discloses 8.3% beneficial stake in Core Laboratories Inc
BlackRock, Inc. has filed an amended Schedule 13G, disclosing an 8.3% beneficial ownership in Core Laboratories Inc (CLB). This stake amounts to 3,811,390 shares, with BlackRock holding sole voting power over 3,703,577 shares and sole dispositive power over all 3,811,390 shares. No single BlackRock client holds more than five percent of Core Laboratories' outstanding common stock.
Core Laboratories (NYSE: CLB) CEO purchases 5,000 shares in open-market trade
Core Laboratories Inc. (NYSE: CLB) Chairman and CEO Bruno Lawrence purchased 5,000 shares of the company's common stock on July 31, 2026, at a price of $10.78 per share in an open-market transaction. This purchase increased his direct holdings to 262,438 shares. The Form 4 filing indicates that no Rule 10b5-1 trading plan was associated with this transaction.
Core Laboratories (NYSE:CLB) CEO Lawrence Bruno Buys 5,000 Shares
Core Laboratories CEO Lawrence Bruno recently purchased 5,000 shares of the company's stock for $53,900, increasing his total ownership to 262,438 shares. This insider buying comes as the company reported Q2 EPS of $0.11, surpassing estimates, though revenue declined by 4.3% year-over-year. Core Laboratories also declared a quarterly dividend of $0.01 per share, while analysts maintain a "Reduce" consensus rating on the stock.
CORE LAB REPORTS SECOND QUARTER 2026 RESULTS
Core Laboratories Inc. reported its second quarter 2026 results, with revenue of $124.6 million, a 2% sequential increase, and GAAP EPS of $0.13. The company highlighted sequential improvements despite geopolitical conflicts impacting its Reservoir Description segment. Core Lab also announced a quarterly dividend and repurchased shares, while projecting sequential revenue growth for the third quarter of 2026.
Is CLB Stock Attractive After Its Sharp Selloff and Mixed Q2 Results?
Core Laboratories (CLB) shares have fallen significantly, making its valuation appear attractive. Despite a lower valuation and an asset-light model, the company faces challenges with falling earnings, geopolitical issues, and uneven operating recovery. While there's potential upside, analysts suggest patience as the stock carries a Zacks Rank #4 (Sell) due to weak estimate revisions and ongoing volatility.
Core Laboratories Q2 Earnings Beat Estimates, Decline Y/Y
Core Laboratories (CLB) reported Q2 2026 adjusted earnings of 11 cents per share, surpassing estimates but declining year-over-year due to underperformance in the Reservoir Description segment and increased costs. Revenues of $124.6 million missed estimates and decreased from the previous year, attributed to geopolitical conflicts impacting energy infrastructure and demand for international laboratory services. Despite the decline, the Production Enhancement segment showed strength, and the company repurchased shares while maintaining a low debt leverage ratio.
Q2 2026 Core Laboratories Inc Earnings Call Transcript
Core Laboratories Inc (CLB) reported mixed results for Q2 2026, with production enhancement revenue increasing by 15% sequentially and 5% year-over-year due to international reservoir characterization projects and proprietary perforating technology. However, reservoir description revenue declined by 4% sequentially and 9% year-over-year, impacted by geopolitical disruptions in the Middle East and expanded sanctions in Russia and Ukraine. The company continued its share repurchase program, buying back over 214,000 shares, and generated $3.1 million in free cash flow, while providing a wide revenue guidance range for Q3 2026 due to ongoing geopolitical uncertainties.
Core Laboratories Q2 Earnings Call Highlights
Core Laboratories reported Q2 2026 revenue of $124.6 million, a 2% increase sequentially but a 4% decrease year-over-year, impacted by Middle East and Russia-Ukraine conflicts. The company's CEO, Larry Bruno, highlighted investments in new technologies and improving conditions outside conflict zones, particularly in Production Enhancement. Despite geopolitical challenges affecting its Reservoir Description segment, Core Lab saw increased energetic product sales and expects sequential growth in Q3.
Core Laboratories Inc. /DE/ Q2 2026: Revenue $124.6M, EPS $0.12— 10-Q Summary
Core Laboratories Inc. /DE/ reported its Q2 2026 financial results with revenue of $124.6 million, marking a 4% year-over-year decrease from $130.2 million in Q2 2025. Diluted earnings per share dropped to $0.12 from $0.23 in the prior year, primarily due to weaker international activity, lower equipment shipments, and disruptions from Middle East conflicts and sanctions. Despite overall declines, the company saw growth in U.S. onshore product sales and well diagnostic services, and continued efforts in carbon capture and geothermal projects.
Core Laboratories: Q2 Earnings Snapshot
This article provides a brief earnings snapshot for Core Laboratories' Q2, but contains no actual financial details or article content beyond the headline. The body of the article is empty, indicating a placeholder or an article that failed to load content.
Press Release: CORE LAB REPORTS SECOND QUARTER 2026 RESULTS
Core Laboratories (NYSE: CLB) announced its second quarter 2026 results. The company reported a revenue of $133.0 million, with a net income of $12.3 million and diluted earnings per share (EPS) of $0.26. Core Lab's CEO, Christopher Hill, highlighted the company's strong financial performance driven by increased demand for its services and products, particularly in international and offshore markets.
Core Laboratories Inc. (NYSE:CLB) Declares $0.01 Quarterly Dividend
Core Laboratories Inc. (NYSE:CLB) announced a quarterly dividend of $0.01 per share, payable on August 31st. The company reported second-quarter EPS of $0.11, exceeding analyst estimates, but revenue declined year-over-year. Despite the earnings beat, the stock traded down 7.7% near its 52-week low, influenced by cautious third-quarter guidance and overall declining annual results.
